BIT Capital GmbH grew its holdings in Axon Enterprise, Inc (NASDAQ: AXON) by 75.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,535 shares of the biotechnology company's stock after purchasing an additional 1,522 shares during the quarter. BIT

Axon Enterprise (AXON) concluded the recent trading session at $441.12, signifying a +2.56% move from its prior day's close.

Beyond analysts' top-and-bottom-line estimates for Axon (AXON), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.

Zacks.com users have recently been watching Axon (AXON) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

HighTower Advisors LLC increased its holdings in Axon Enterprise, Inc (NASDAQ: AXON) by 4.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,601 shares of the biotechnology company's stock after purchasing an additional 1,997 shares during the quarter. HighTower Advisors

NEOS Investment Management LLC raised its stake in Axon Enterprise, Inc (NASDAQ: AXON) by 82.7% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,369 shares of the biotechnology company's stock after purchasing an additional 11,482 shares during the period. NEOS

Illinois Municipal Retirement Fund decreased its holdings in Axon Enterprise, Inc (NASDAQ: AXON) by 47.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,009 shares of the biotechnology company's stock after selling 1,845 shares during the period. Illinois Municipal

We invest in secular growth and innovative businesses across all market capitalizations, with the bulk of the portfolio landing in the large-cap zone. We recently initiated a position in Axon Enterprise. We exited our successful investment in Exact Sciences Corporation after Abbott Laboratories announced it was acquiring the company for approximately $23 billion in cash.

The latest trading day saw Axon Enterprise (AXON) settling at $434.45, representing a -2.8% change from its previous close.

My methodology blends forward P/E ratios, company size, and default risk to rank Nasdaq 100 constituents by valuation. TSLA, INTC, AXON, PLTR, and CRWD are the most overvalued; PYPL, CTSH, ADBE, KHC, and PAYX are the most undervalued. Despite a $2.3trn market cap for the top 5 overvalued stocks, analysts expect higher earnings growth from the undervalued group.